{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:02:17Z","timestamp":1793034137932,"version":"4.5.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Panco Healthcare Co., Ltd., A Pharmaessentia Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Janus kinase 2 (\n                    <jats:italic>JAK2<\/jats:italic>\n                    ) V617F mutation is present in most patients with polycythemia vera (PV). One persistently puzzling aspect unresolved is the association between\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F allele burden (also known as variant allele frequency) and the relevant clinical characteristics. Numerous studies have reported associations between allele burden and both hematologic and clinical features. While there are strong indications linking high allele burden in PV patients with symptoms and clinical characteristics, not all associations are definitive, and disparate and contradictory findings have been reported. Hence, this study aimed to synthesize existing data from the literature to better understand the association between\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F allele burden and relevant clinical correlates. Out of the 1,851 studies identified, 39 studies provided evidence related to the association between\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F allele burden and clinical correlates, and 21 studies were included in meta-analyses. Meta-analyses of correlation demonstrated that leucocyte and erythrocyte counts were significantly and positively correlated with\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F allele burden, whereas platelet count was not. Meta-analyses of standardized mean difference demonstrated that leucocyte and hematocrit were significantly higher in patients with higher\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F allele burden, whereas platelet count was significantly lower. Meta-analyses of odds ratio demonstrated that patients who had higher\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F allele burden had a significantly greater odds ratio for developing pruritus, splenomegaly, thrombosis, myelofibrosis, and acute myeloid leukemia. Our study integrates data from approximately 5,462 patients, contributing insights into the association between\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F allele burden and various hematological parameters, symptomatic manifestations, and complications. However, varied methods of data presentation and statistical analyses prevented the execution of high-quality meta-analyses.\n                  <\/jats:p>","DOI":"10.1007\/s00277-024-05754-4","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:01:43Z","timestamp":1713830503000},"page":"1947-1965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6794-7229","authenticated-orcid":false,"given":"Chih-Cheng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-0315","authenticated-orcid":false,"given":"Justin L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3511-2390","authenticated-orcid":false,"given":"Alex Jia-Hong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7492-5570","authenticated-orcid":false,"given":"Lennex Hsueh-Lin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2780-4845","authenticated-orcid":false,"given":"Hsin-An","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"issue":"9464","key":"5754_CR1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [published correction appears in Lancet. 2005 Jul 9\u201315;366(9480):122]. Lancet 365(9464):1054\u20131061. https:\/\/doi.org\/10.1016\/S0140-6736(05)71142-9","journal-title":"Lancet"},{"issue":"4","key":"5754_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387\u2013397. https:\/\/doi.org\/10.1016\/j.ccr.2005.03.023","journal-title":"Cancer Cell"},{"issue":"5","key":"5754_CR3","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/blood-2005-10-009514","volume":"108","author":"L Gar\u00e7on","year":"2006","unstructured":"Gar\u00e7on L, Rivat C, James C et al (2006) Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood 108(5):1551\u20131554. https:\/\/doi.org\/10.1182\/blood-2005-10-009514","journal-title":"Blood"},{"issue":"4","key":"5754_CR4","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","volume":"108","author":"R Kralovics","year":"2006","unstructured":"Kralovics R, Teo SS, Li S et al (2006) Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 108(4):1377\u20131380. https:\/\/doi.org\/10.1182\/blood-2005-11-009605","journal-title":"Blood"},{"issue":"21","key":"5754_CR5","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1038\/sj.onc.1205398","volume":"21","author":"SG Rane","year":"2002","unstructured":"Rane SG, Reddy EP (2002) JAKs, STATs and Src kinases in hematopoiesis. Oncogene 21(21):3334\u20133358. https:\/\/doi.org\/10.1038\/sj.onc.1205398","journal-title":"Oncogene"},{"issue":"17","key":"5754_CR6","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","volume":"115","author":"H Akada","year":"2010","unstructured":"Akada H, Yan D, Zou H et al (2010) Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 115(17):3589\u20133597. https:\/\/doi.org\/10.1182\/blood-2009-04-215848","journal-title":"Blood"},{"issue":"1","key":"5754_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1182\/asheducation-2014.1.287","volume":"2014","author":"J Nangalia","year":"2014","unstructured":"Nangalia J, Green TR (2014) The evolving genomic landscape of myeloproliferative neoplasms. Hematol Am Soc Hematol Educ Program 2014(1):287\u2013296. https:\/\/doi.org\/10.1182\/asheducation-2014.1.287Epub 2014 Nov 18. PMID: 25696868","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"5","key":"5754_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356(5):459\u2013468. https:\/\/doi.org\/10.1056\/NEJMoa065202","journal-title":"N Engl J Med"},{"issue":"5","key":"5754_CR9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ajh.23676","volume":"89","author":"A Alvarez-Larr\u00e1n","year":"2014","unstructured":"Alvarez-Larr\u00e1n A, Bellosillo B, Pereira A et al (2014) JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol 89(5):517\u2013523. https:\/\/doi.org\/10.1002\/ajh.23676","journal-title":"Am J Hematol"},{"key":"5754_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol 134:103\u2013112. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.02.003","journal-title":"J Clin Epidemiol"},{"key":"5754_CR11","doi-asserted-by":"crossref","unstructured":"Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K, Mu P-F (2020) Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis. JBI, https:\/\/synthesismanual.jbi.global","DOI":"10.46658\/JBIRM-17-06"},{"issue":"12","key":"5754_CR12","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/ajh.24191","volume":"90","author":"J Bai","year":"2015","unstructured":"Bai J, Ai L, Zhang L, Yang FC, Zhou Y, Xue Y (2015) Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. Am J Hematol 90(12):1116\u20131121. https:\/\/doi.org\/10.1002\/ajh.24191","journal-title":"Am J Hematol"},{"issue":"2","key":"5754_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3324\/haematol.2010.031070","volume":"96","author":"T Barbui","year":"2011","unstructured":"Barbui T, Carobbio A, Finazzi G et al (2011) Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 96(2):315\u2013318. https:\/\/doi.org\/10.3324\/haematol.2010.031070","journal-title":"Haematologica"},{"issue":"1","key":"5754_CR14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/blood-2005-12-4852","volume":"108","author":"C Bellann\u00e9-Chantelot","year":"2006","unstructured":"Bellann\u00e9-Chantelot C, Chaumarel I, Labopin M et al (2006) Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 108(1):346\u2013352. https:\/\/doi.org\/10.1182\/blood-2005-12-4852","journal-title":"Blood"},{"issue":"9","key":"5754_CR15","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","volume":"37","author":"A Carobbio","year":"2009","unstructured":"Carobbio A, Finazzi G, Antonioli E et al (2009) JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol 37(9):1016\u20131021. https:\/\/doi.org\/10.1016\/j.exphem.2009.06.006","journal-title":"Exp Hematol"},{"key":"5754_CR16","doi-asserted-by":"publisher","first-page":"453020","DOI":"10.1155\/2015\/453020","volume":"2015","author":"VP \u010coki\u0107","year":"2015","unstructured":"\u010coki\u0107 VP, Mitrovi\u0107-Ajti\u0107 O, Beleslin-\u010coki\u0107 BB et al (2015) Proinflammatory cytokine IL-6 and JAK-STAT signaling pathway in Myeloproliferative Neoplasms. Mediators Inflamm 2015:453020. https:\/\/doi.org\/10.1155\/2015\/453020","journal-title":"Mediators Inflamm"},{"issue":"1","key":"5754_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12185-013-1475-9","volume":"99","author":"M Coucelo","year":"2014","unstructured":"Coucelo M, Caetano G, Sevivas T et al (2014) JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients. Int J Hematol 99(1):32\u201340. https:\/\/doi.org\/10.1007\/s12185-013-1475-9","journal-title":"Int J Hematol"},{"issue":"5","key":"5754_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s12185-014-1567-1","volume":"99","author":"Y Edahiro","year":"2014","unstructured":"Edahiro Y, Morishita S, Takahashi K et al (2014) JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. Int J Hematol 99(5):625\u2013634. https:\/\/doi.org\/10.1007\/s12185-014-1567-1","journal-title":"Int J Hematol"},{"issue":"5","key":"5754_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/ijlh.12381","volume":"37","author":"S Ferdowsi","year":"2015","unstructured":"Ferdowsi S, Atarodi K, Amirizadeh N et al (2015) Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings. Int J Lab Hematol 37(5):661\u2013667. https:\/\/doi.org\/10.1111\/ijlh.12381","journal-title":"Int J Lab Hematol"},{"issue":"2","key":"5754_CR20","first-page":"70","volume":"10","author":"S Ferdowsi","year":"2016","unstructured":"Ferdowsi S, Ghaffari SH, Amirizadeh N et al (2016) JAK2V617F Allele Burden Measurement in Peripheral blood of Iranian patients with myeloproliferative neoplasms and effect of Hydroxyurea on JAK2V617F Allele Burden. Int J Hematol Oncol Stem Cell Res 10(2):70\u201378","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"6","key":"5754_CR21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/ajh.21156","volume":"83","author":"N Gangat","year":"2008","unstructured":"Gangat N, Strand JJ, Lasho TL, Li CY, Pardanani A, Tefferi A (2008) Pruritus in Polycythemia vera is associated with a lower risk of arterial thrombosis. Am J Hematol 83(6):451\u2013453. https:\/\/doi.org\/10.1002\/ajh.21156","journal-title":"Am J Hematol"},{"issue":"3","key":"5754_CR22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1600-0609.2007.01003.x","volume":"80","author":"N Gangat","year":"2008","unstructured":"Gangat N, Strand J, Lasho TL et al (2008) Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol 80(3):197\u2013200. https:\/\/doi.org\/10.1111\/j.1600-0609.2007.01003.x","journal-title":"Eur J Haematol"},{"issue":"1\u20132","key":"5754_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cellimm.2012.07.003","volume":"278","author":"S Gangemi","year":"2012","unstructured":"Gangemi S, Allegra A, Pace E et al (2012) Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia. Cell Immunol 278(1\u20132):91\u201394. https:\/\/doi.org\/10.1016\/j.cellimm.2012.07.003","journal-title":"Cell Immunol"},{"issue":"6","key":"5754_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3343\/alm.2012.32.6.385","volume":"32","author":"JS Ha","year":"2012","unstructured":"Ha JS, Kim YK, Jung SI, Jung HR, Chung IS (2012) Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms. Ann Lab Med 32(6):385\u2013391. https:\/\/doi.org\/10.3343\/alm.2012.32.6.385","journal-title":"Ann Lab Med"},{"issue":"6","key":"5754_CR25","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1080\/10245332.2016.1267830","volume":"22","author":"L Hu","year":"2017","unstructured":"Hu L, Pu L, Ding Y et al (2017) Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms. Hematology 22(6):354\u2013360. https:\/\/doi.org\/10.1080\/10245332.2016.1267830","journal-title":"Hematology"},{"issue":"11","key":"5754_CR26","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.3109\/10428194.2012.682308","volume":"53","author":"M Koren-Michowitz","year":"2012","unstructured":"Koren-Michowitz M, Landman J, Cohen Y et al (2012) JAK2V617F allele burden is associated with transformation to myelofibrosis. Leuk Lymphoma 53(11):2210\u20132213. https:\/\/doi.org\/10.3109\/10428194.2012.682308","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"5754_CR27","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/j.1600-0609.2007.00960.x","volume":"79","author":"TS Larsen","year":"2007","unstructured":"Larsen TS, Pallisgaard N, M\u00f8ller MB, Hasselbalch HC (2007) The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis\u2013impact on disease phenotype. Eur J Haematol 79(6):508\u2013515. https:\/\/doi.org\/10.1111\/j.1600-0609.2007.00960.x","journal-title":"Eur J Haematol"},{"issue":"4","key":"5754_CR28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5045\/br.2021.2021089","volume":"56","author":"AJ Lee","year":"2021","unstructured":"Lee AJ, Kim SG, Nam JY, Yun J, Ryoo HM, Bae SH (2021) Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden. Blood Res 56(4):259\u2013265. https:\/\/doi.org\/10.5045\/br.2021.2021089","journal-title":"Blood Res"},{"issue":"3","key":"5754_CR29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00277-016-2890-9","volume":"96","author":"D Lekovic","year":"2017","unstructured":"Lekovic D, Gotic M, Skoda R et al (2017) Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. Ann Hematol 96(3):393\u2013404. https:\/\/doi.org\/10.1007\/s00277-016-2890-9","journal-title":"Ann Hematol"},{"issue":"3\u20134","key":"5754_CR30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.bcmd.2012.06.004","volume":"49","author":"S Malak","year":"2012","unstructured":"Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A, French Group of Familial Myeloproliferative Disorders (2012) Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. Blood Cells Mol Dis 49(3\u20134):170\u2013176. https:\/\/doi.org\/10.1016\/j.bcmd.2012.06.004","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"5754_CR31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/bjh.17848","volume":"196","author":"N Maslah","year":"2022","unstructured":"Maslah N, Ravdan O, Drevon L et al (2022) Revisiting diagnostic performances of serum erythropo\u00efetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement. Br J Haematol 196(3):676\u2013680. https:\/\/doi.org\/10.1111\/bjh.17848","journal-title":"Br J Haematol"},{"issue":"11","key":"5754_CR32","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.exphem.2008.05.006","volume":"36","author":"AR Moliterno","year":"2008","unstructured":"Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL (2008) Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol 36(11):1480\u20131486. https:\/\/doi.org\/10.1016\/j.exphem.2008.05.006","journal-title":"Exp Hematol"},{"key":"5754_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.leukres.2015.11.002","volume":"40","author":"M Okabe","year":"2016","unstructured":"Okabe M, Yamaguchi H, Usuki K et al (2016) Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L\/K mutations. Leuk Res 40:68\u201376. https:\/\/doi.org\/10.1016\/j.leukres.2015.11.002","journal-title":"Leuk Res"},{"issue":"9","key":"5754_CR34","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/leu.2010.148","volume":"24","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Rumi E, Pietra D et al (2010) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 24(9):1574\u20131579. https:\/\/doi.org\/10.1038\/leu.2010.148","journal-title":"Leukemia"},{"issue":"6","key":"5754_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.clml.2014.02.013","volume":"14","author":"KB Payzin","year":"2014","unstructured":"Payzin KB, Savasoglu K, Alacacioglu I et al (2014) JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk 14(6):525\u2013533. https:\/\/doi.org\/10.1016\/j.clml.2014.02.013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"5754_CR36","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3324\/haematol.2009.007047","volume":"94","author":"L Pieri","year":"2009","unstructured":"Pieri L, Bogani C, Guglielmelli P et al (2009) The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica 94(11):1537\u20131545. https:\/\/doi.org\/10.3324\/haematol.2009.007047","journal-title":"Haematologica"},{"issue":"2","key":"5754_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2478\/bjmg-2019-0021","volume":"22","author":"M Popova-Labachevska","year":"2019","unstructured":"Popova-Labachevska M, Panovska-Stavridis I, Eftimov A et al (2019) Evaluation of the JAK2V617F mutational burden in patients with Philadelphia chromosome negative myeloproliferative neoplasms: a single-center experience. Balkan J Med Genet 22(2):31\u201336 Published 2019 Dec 21. https:\/\/doi.org\/10.2478\/bjmg-2019-0021","journal-title":"Balkan J Med Genet"},{"issue":"7","key":"5754_CR38","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.exphem.2013.03.007","volume":"41","author":"M Ruella","year":"2013","unstructured":"Ruella M, Salmoiraghi S, Risso A et al (2013) Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. Exp Hematol 41(7):627\u2013634. https:\/\/doi.org\/10.1016\/j.exphem.2013.03.007","journal-title":"Exp Hematol"},{"issue":"3","key":"5754_CR39","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/rth2.12315","volume":"4","author":"M Sacco","year":"2020","unstructured":"Sacco M, Ranalli P, Lancellotti S et al (2020) Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia. Res Pract Thromb Haemost 4(3):413\u2013421 Published 2020 Feb 28. https:\/\/doi.org\/10.1002\/rth2.12315","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"5754_CR40","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/sajc.sajc_161_18","volume":"8","author":"S Sazawal","year":"2019","unstructured":"Sazawal S, Singh K, Chhikara S, Chaubey R, Mahapatra M, Saxena R (2019) Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: a study from India. South Asian J Cancer 8(2):127\u2013129. https:\/\/doi.org\/10.4103\/sajc.sajc_161_18","journal-title":"South Asian J Cancer"},{"issue":"2","key":"5754_CR41","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.leukres.2010.06.017","volume":"35","author":"RT Silver","year":"2011","unstructured":"Silver RT, Vandris K, Wang YL et al (2011) JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res 35(2):177\u2013182. https:\/\/doi.org\/10.1016\/j.leukres.2010.06.017","journal-title":"Leuk Res"},{"key":"5754_CR42","doi-asserted-by":"publisher","first-page":"874146","DOI":"10.1155\/2011\/874146","volume":"2011","author":"BL Stein","year":"2011","unstructured":"Stein BL, Rademaker A, Spivak JL, Moliterno AR (2011) Gender and vascular complications in the JAK2 V617F-Positive myeloproliferative neoplasms. Thrombosis 2011:874146. https:\/\/doi.org\/10.1155\/2011\/874146","journal-title":"Thrombosis"},{"issue":"9","key":"5754_CR43","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.3109\/10428194.2012.759656","volume":"54","author":"BL Stein","year":"2013","unstructured":"Stein BL, Saraf S, Sobol U et al (2013) Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma 54(9):1989\u20131995. https:\/\/doi.org\/10.3109\/10428194.2012.759656","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"5754_CR44","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1038\/sj.leu.2404724","volume":"21","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Strand JJ, Lasho TL et al (2007) Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 21(9):2074\u20132075. https:\/\/doi.org\/10.1038\/sj.leu.2404724","journal-title":"Leukemia"},{"issue":"9","key":"5754_CR45","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","volume":"21","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P et al (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21(9):1952\u20131959. https:\/\/doi.org\/10.1038\/sj.leu.2404854","journal-title":"Leukemia"},{"issue":"3","key":"5754_CR46","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","volume":"110","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P et al (2007) Clinical profile of homozygous JAK2 617V\u2009>\u2009F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110(3):840\u2013846. https:\/\/doi.org\/10.1182\/blood-2006-12-064287","journal-title":"Blood"},{"issue":"1","key":"5754_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7150\/ijms.10539","volume":"13","author":"S Zhao","year":"2016","unstructured":"Zhao S, Zhang X, Xu Y et al (2016) Impact of JAK2V617F mutation burden on Disease phenotype in Chinese patients with JAK2V617F-positive Polycythemia Vera (PV) and essential thrombocythemia (ET). Int J Med Sci 13(1):85\u201391 Published 2016 Jan 25. https:\/\/doi.org\/10.7150\/ijms.10539","journal-title":"Int J Med Sci"},{"issue":"2","key":"5754_CR48","doi-asserted-by":"publisher","first-page":"e57856","DOI":"10.1371\/journal.pone.0057856","volume":"8","author":"J Zhou","year":"2013","unstructured":"Zhou J, Ye Y, Zeng S et al (2013) Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts. PLoS ONE 8(2):e57856. https:\/\/doi.org\/10.1371\/journal.pone.0057856","journal-title":"PLoS ONE"},{"issue":"12","key":"5754_CR49","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","volume":"11","author":"P Guglielmelli","year":"2021","unstructured":"Guglielmelli P, Loscocco GG, Mannarelli C et al (2021) JAK2V617F variant allele frequency\u2009>\u200950% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J 11(12):199 Published 2021 Dec 11. https:\/\/doi.org\/10.1038\/s41408-021-00581-6","journal-title":"Blood Cancer J"},{"issue":"1","key":"5754_CR50","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ejh.12552","volume":"96","author":"A Alvarez-Larr\u00e1n","year":"2016","unstructured":"Alvarez-Larr\u00e1n A, Angona A, Ancochea A et al (2016) Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes. Eur J Haematol 96(1):83\u201389","journal-title":"Eur J Haematol"},{"issue":"5","key":"5754_CR51","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/bjh.14762","volume":"178","author":"A Alvarez-Larr\u00e1n","year":"2017","unstructured":"Alvarez-Larr\u00e1n A, Sen\u00edn A, Fern\u00e1ndez-Rodr\u00edguez C et al (2017) Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. Br J Haematol 178(5):764\u2013771. https:\/\/doi.org\/10.1111\/bjh.14762","journal-title":"Br J Haematol"},{"issue":"3","key":"5754_CR52","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/bjh.13047","volume":"167","author":"\u00c0 Ancochea","year":"2014","unstructured":"Ancochea \u00c0, \u00c1lvarez-Larr\u00e1n A, Morales\u2010Indiano C et al (2014) The role of serum erythropoietin level and jak2 v617f allele burden in the diagnosis of polycythaemia vera. Br J Haematol 167(3):411\u2013417","journal-title":"Br J Haematol"},{"issue":"7","key":"5754_CR53","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.leukres.2014.04.002","volume":"38","author":"CL Andersen","year":"2014","unstructured":"Andersen CL, Bj\u00f8rn ME, McMullin MF et al (2014) Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leuk Res 38(7):816\u2013821","journal-title":"Leuk Res"},{"issue":"5","key":"5754_CR54","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/bjh.16450","volume":"189","author":"B Andr\u00e9asson","year":"2020","unstructured":"Andr\u00e9asson B, Pettersson H, Wasslavik C, Johansson P, Palmqvist L, Asp J (2020) ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO-defined polycythaemia vera patients. Br J Haematol 189(5):913\u2013919","journal-title":"Br J Haematol"},{"issue":"10","key":"5754_CR55","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","volume":"119","author":"T Barbui","year":"2012","unstructured":"Barbui T, Thiele J, Passamonti F et al (2012) Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 119(10):2239\u20132241","journal-title":"Blood"},{"issue":"11","key":"5754_CR56","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/ajh.24851","volume":"92","author":"T Barbui","year":"2017","unstructured":"Barbui T, Vannucchi AM, Finazzi G et al (2017) A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity\u2010matched study. Am J Hematol 92(11):1131\u20131136","journal-title":"Am J Hematol"},{"issue":"Suppl 2","key":"5754_CR57","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/HS9.0000000000000115","volume":"2","author":"G Barosi","year":"2018","unstructured":"Barosi G (2018) Spleen in myeloproliferative neoplasms. Hemasphere 2(Suppl 2):173\u2013174 Published 2018 Jun 11. https:\/\/doi.org\/10.1097\/HS9.0000000000000115","journal-title":"Hemasphere"},{"key":"5754_CR58","doi-asserted-by":"crossref","unstructured":"Benati M, Montagnana M, Danese E et al (2015) Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms. Clin Chem Lab Med (CCLM). ;53(7)","DOI":"10.1515\/cclm-2014-0858"},{"issue":"11","key":"5754_CR59","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/cncr.31986","volume":"125","author":"CB Benton","year":"2019","unstructured":"Benton CB, Boddu PC, DiNardo CD et al (2019) Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer 125(11):1855\u20131866. https:\/\/doi.org\/10.1002\/cncr.31986","journal-title":"Cancer"},{"issue":"8","key":"5754_CR60","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00277-017-3040-8","volume":"96","author":"I Bertozzi","year":"2017","unstructured":"Bertozzi I, Bogoni G, Biagetti G et al (2017) Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. Ann Hematol 96(8):1297\u20131302","journal-title":"Ann Hematol"},{"issue":"2","key":"5754_CR61","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.thromres.2014.11.006","volume":"135","author":"M Borowczyk","year":"2015","unstructured":"Borowczyk M, Wojtaszewska M, Lewandowski K et al (2015) The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Thromb Res 135(2):272\u2013280","journal-title":"Thromb Res"},{"issue":"3","key":"5754_CR62","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000348413","volume":"130","author":"H Chang","year":"2013","unstructured":"Chang H, Shih L, Michelson AD et al (2013) Clinical and Laboratory significance of defective P2Y\u2009<\u2009sub\u2009>\u200912\u2009pathway function in patients with myeloproliferative neoplasms: a pilot study. Acta Haematol 130(3):181\u2013187","journal-title":"Acta Haematol"},{"issue":"10","key":"5754_CR63","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.clml.2020.05.019","volume":"20","author":"A Coltoff","year":"2020","unstructured":"Coltoff A, Mesa R, Gotlib J et al (2020) Real-world outcomes of Ruxolitinib Treatment for Polycythemia Vera. Clin Lymphoma Myeloma Leuk 20(10):697\u2013703e1. https:\/\/doi.org\/10.1016\/j.clml.2020.05.019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"5754_CR64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-017-0395-1","volume":"10","author":"E Cris\u00e0","year":"2017","unstructured":"Cris\u00e0 E, Cerrano M, Beggiato E et al (2017) Can pegylated interferon improve the outcome of polycythemia vera patients? J Hematol Oncol 10(1):15. https:\/\/doi.org\/10.1186\/s13045-017-0395-1. Published 2017 Jan 13","journal-title":"J Hematol Oncol"},{"issue":"15","key":"5754_CR65","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1182\/bloodadvances.2020002414","volume":"4","author":"P Debureaux","year":"2020","unstructured":"Debureaux P, Cassinat B, Soret-Dulphy J et al (2020) Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Blood Adv 4(15):3708\u20133715","journal-title":"Blood Adv"},{"issue":"6","key":"5754_CR66","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1182\/bloodadvances.2019001379","volume":"4","author":"R Gangaraju","year":"2020","unstructured":"Gangaraju R, Song J, Kim SJ et al (2020) Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv 4(6):1115\u20131130","journal-title":"Blood Adv"},{"issue":"2","key":"5754_CR67","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/bjh.17087","volume":"192","author":"N Garcia-Gisbert","year":"2021","unstructured":"Garcia-Gisbert N, Fern\u00e1ndez-Ibarrondo L, Fern\u00e1ndez-Rodr\u00edguez C et al (2021) Circulating cell-free DNA improves the molecular characterisation of Ph-negative myeloproliferative neoplasms. Br J Haematol 192(2):300\u2013309. https:\/\/doi.org\/10.1111\/bjh.17087","journal-title":"Br J Haematol"},{"issue":"5","key":"5754_CR68","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1111\/bjh.16624","volume":"189","author":"N Garcia-Gisbert","year":"2020","unstructured":"Garcia-Gisbert N, Camacho L, Fern\u00e1ndez-Ibarrondo L et al (2020) Analysis of saliva samples and cluster of differentiation 3 (CD3)\u2009+\u2009lymphocytes as a source of germline DNA in myeloproliferative neoplasms. Br J Haematol 189(5):e204\u2013e207. https:\/\/doi.org\/10.1111\/bjh.16624","journal-title":"Br J Haematol"},{"issue":"10","key":"5754_CR69","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1182\/blood-2011-08-371328","volume":"119","author":"F Giona","year":"2012","unstructured":"Giona F, Teofili L, Moleti ML et al (2012) Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood 119(10):2219\u20132227","journal-title":"Blood"},{"key":"5754_CR70","doi-asserted-by":"publisher","unstructured":"Gupta V, Kennedy JA, Capo-Chichi JM et al (2021) Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase [published correction appears in Blood Adv. ;5(11):2518]. Blood Adv. 2020;4(21):5562\u20135573. https:\/\/doi.org\/10.1182\/bloodadvances.2020002727","DOI":"10.1182\/bloodadvances.2020002727"},{"issue":"4","key":"5754_CR71","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13577-020-00370-6","volume":"33","author":"SA Guru","year":"2020","unstructured":"Guru SA, Sumi MP, Mir R et al (2020) Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5. Hum Cell 33(4):1099\u20131111","journal-title":"Hum Cell"},{"issue":"3","key":"5754_CR72","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1097\/HS9.0000000000000364","volume":"4","author":"A Guy","year":"2020","unstructured":"Guy A, Danaee A, Paschalaki K et al (2020) Absence of JAK2V617F mutated endothelial colony-forming cells in patients with JAK2V617F myeloproliferative neoplasms and splanchnic vein thrombosis. Hemasphere 4(3):e364 Published 2020 May 5. https:\/\/doi.org\/10.1097\/HS9.0000000000000364","journal-title":"Hemasphere"},{"issue":"2","key":"5754_CR73","first-page":"173","volume":"44","author":"JS Ha","year":"2014","unstructured":"Ha JS, Jeon DS, Kim JR, Ryoo NH, Suh JS (2014) Analysis of the Ten-Eleven translocation 2 (TET2) gene mutation in myeloproliferative neoplasms. Ann Clin Lab Sci 44(2):173\u2013179","journal-title":"Ann Clin Lab Sci"},{"issue":"7","key":"5754_CR74","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3390\/cancers12071891","volume":"12","author":"S Heibl","year":"2020","unstructured":"Heibl S, Gisslinger B, J\u00e4ger E et al (2020) Clinical, hematologic, biologic and molecular characteristics of patients with myeloproliferative neoplasms and a Chronic Myelomonocytic Leukemia-Like phenotype. Cancers (Basel) 12(7):1891","journal-title":"Cancers (Basel)"},{"issue":"10","key":"5754_CR75","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.exphem.2009.07.005","volume":"37","author":"K Hussein","year":"2009","unstructured":"Hussein K, Bock O, Theophile K et al (2009) JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 37(10):1186\u20131193e7","journal-title":"Exp Hematol"},{"issue":"12","key":"5754_CR76","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1182\/bloodadvances.2019001407","volume":"4","author":"T Karantanos","year":"2020","unstructured":"Karantanos T, Chaturvedi S, Braunstein EM et al (2020) Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood Adv 4(12):2567\u20132576","journal-title":"Blood Adv"},{"issue":"4","key":"5754_CR77","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/MBC.0000000000000293","volume":"26","author":"J Kissova","year":"2015","unstructured":"Kissova J, Ovesna P, Bulikova A, Zav\u0159elova J, Penka M (2015) Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience. Blood Coagul Fibrinolysis 26(4):448\u2013453","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"9","key":"5754_CR78","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1080\/10428190802258972","volume":"49","author":"T Kondo","year":"2008","unstructured":"Kondo T, Okuno N, Naruse H et al (2008) Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm. Leuk Lymphoma 49(9):1784\u20131791","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 2","key":"5754_CR79","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/HS9.0000000000000106","volume":"2","author":"S Koschmieder","year":"2018","unstructured":"Koschmieder S, Chatain N (2018) Inflammation and anti-inflammatory approaches in myeloproliferative neoplasm. Hemasphere 2(Suppl 2):143\u2013145 Published 2018 Jun 11. https:\/\/doi.org\/10.1097\/HS9.0000000000000106","journal-title":"Hemasphere"},{"key":"5754_CR80","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40164-016-0057-y","volume":"5","author":"M Kovacsovics-Bankowski","year":"2015","unstructured":"Kovacsovics-Bankowski M, Kelley TW, Efimova O et al (2015) Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2V617F allelic burden. Exp Hematol Oncol 5:28","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"5754_CR81","first-page":"236","volume":"20","author":"A Kurtovic-Kozaric","year":"2020","unstructured":"Kurtovic-Kozaric A, Islamagic E, Komic H et al (2020) The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up. Bosn J Basic Med Sci 20(2):236\u2013247","journal-title":"Bosn J Basic Med Sci"},{"issue":"6","key":"5754_CR82","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1179\/102453309X12473408860587","volume":"14","author":"TS Larsen","year":"2009","unstructured":"Larsen TS, M\u00f8ller MB, de Stricker K et al (2009) Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 14(6):331\u2013334","journal-title":"Hematology"},{"issue":"2","key":"5754_CR83","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1179\/102453308X315960","volume":"13","author":"TS Larsen","year":"2008","unstructured":"Larsen TS, Pallisgaard N, M\u00f8ller MB, Hasselbalch HC (2008) High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. Hematology 13(2):71\u201376","journal-title":"Hematology"},{"issue":"1","key":"5754_CR84","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/sj.leu.2404861","volume":"22","author":"TS Larsen","year":"2008","unstructured":"Larsen TS, Pallisgaard N, M\u00f8ller MB, Hasselbalch HC (2008) Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow. Leukemia 22(1):194\u2013195","journal-title":"Leukemia"},{"issue":"9","key":"5754_CR85","doi-asserted-by":"publisher","first-page":"e569","DOI":"10.1016\/j.clml.2020.04.010","volume":"20","author":"W Limvorapitak","year":"2020","unstructured":"Limvorapitak W, Parker J, Hughesman C, McNeil K, Foltz L, Karsan A (2020) No differences in outcomes between JAK2 V617F\u2013Positive patients with variant allele fraction\u2009<\u20092% versus 2\u201310%: a 6-Year Province-wide retrospective analysis. Clin Lymphoma Myeloma Leuk 20(9):e569\u2013e578","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"5754_CR86","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/gcc.22437","volume":"56","author":"D Luque Paz","year":"2017","unstructured":"Luque Paz D, Chauveau A, Boyer F et al (2017) Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome. Genes Chromosomes Cancer 56(5):354\u2013362","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"5754_CR87","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-017-0425-z","volume":"10","author":"F Lussana","year":"2017","unstructured":"Lussana F, Carobbio A, Salmoiraghi S et al (2017) Driver mutations (JAK2V617F, MPLW515L\/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol 10(1):54","journal-title":"J Hematol Oncol"},{"issue":"4","key":"5754_CR88","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/genes12040559","volume":"12","author":"TV Makarik","year":"2021","unstructured":"Makarik TV, Abdullaev AO, Nikulina EE et al (2021) Low JAK2 V617F allele Burden in Ph-Negative chronic myeloproliferative neoplasms is Associated with additional CALR or MPL gene mutations. Genes (Basel) 12(4):559","journal-title":"Genes (Basel)"},{"issue":"8","key":"5754_CR89","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1016\/j.clml.2019.05.005","volume":"19","author":"MM Mattar","year":"2019","unstructured":"Mattar MM, Nassef S, El Husseiny NM et al (2019) Incidence of silent thrombosis in patients younger than 60 years with myeloproliferative neoplasms: single-center Egyptian study. Clin Lymphoma Myeloma Leuk 19(8):e425\u2013e429","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"5754_CR90","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s00277-016-2765-0","volume":"95","author":"MM Mattar","year":"2016","unstructured":"Mattar MM, Morad MA, El Husseiny NM, Ali NH, El Demerdash DM (2016) Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience. Ann Hematol 95(10):1611\u20131616","journal-title":"Ann Hematol"},{"issue":"4","key":"5754_CR91","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ajh.26461","volume":"97","author":"JD Milosevic Feenstra","year":"2022","unstructured":"Milosevic Feenstra JD, J\u00e4ger R, Schischlik F et al (2022) PD-L1 overexpression correlates with JAK2\u2010V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. Am J Hematol 97(4):390\u2013400","journal-title":"Am J Hematol"},{"issue":"6","key":"5754_CR92","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s12185-018-2421-7","volume":"107","author":"K Misawa","year":"2018","unstructured":"Misawa K, Yasuda H, Araki M et al (2018) Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol 107(6):673\u2013680","journal-title":"Int J Hematol"},{"key":"5754_CR93","doi-asserted-by":"publisher","first-page":"777730","DOI":"10.3389\/fonc.2021.777730","volume":"11","author":"R Moia","year":"2021","unstructured":"Moia R, Cittone MG, Boggione P et al (2021) Stiffer spleen predicts higher bone marrow fibrosis and higher JAK2 allele Burden in patients with myeloproliferative neoplasms. Front Oncol 11:777730","journal-title":"Front Oncol"},{"key":"5754_CR94","doi-asserted-by":"publisher","unstructured":"Nangalia J, Bench AJ, Green AR, Godfrey AL (2019) Myeloproliferative neoplasms. In Molecular Hematology (eds D. Provan and J. Gribben). https:\/\/doi.org\/10.1002\/9781119252863.ch7","DOI":"10.1002\/9781119252863.ch7"},{"issue":"1","key":"5754_CR95","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41379-020-0624-y","volume":"34","author":"CY Ok","year":"2021","unstructured":"Ok CY, Trowell KT, Parker KG et al (2021) Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2\/MPL\/CALR) and SF3B1. Mod Pathol 34(1):20\u201331. https:\/\/doi.org\/10.1038\/s41379-020-0624-y","journal-title":"Mod Pathol"},{"issue":"4","key":"5754_CR96","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ajh.21974","volume":"86","author":"M Panova-Noeva","year":"2011","unstructured":"Panova-Noeva M, Marchetti M, Spronk HM et al (2011) Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. Am J Hematol 86(4):337\u2013342","journal-title":"Am J Hematol"},{"issue":"2","key":"5754_CR97","doi-asserted-by":"publisher","first-page":"128","DOI":"10.5045\/br.2013.48.2.128","volume":"48","author":"SH Park","year":"2013","unstructured":"Park SH, Chi HS, Cho YU, Jang S, Park CJ (2013) The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasm. Blood Res 48(2):128\u2013132","journal-title":"Blood Res"},{"issue":"3","key":"5754_CR98","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.1097\/HS9.0000000000000233","volume":"3","author":"S Pearson","year":"2019","unstructured":"Pearson S, Blance R, Somervaille TCP, Whetton AD, Pierce A (2019) AXL Inhibition extinguishes primitive JAK2 mutated myeloproliferative neoplasm progenitor cells. Hemasphere 3(3):e233 Published 2019 Jun 4. https:\/\/doi.org\/10.1097\/HS9.0000000000000233","journal-title":"Hemasphere"},{"issue":"23","key":"5754_CR99","doi-asserted-by":"publisher","first-page":"37239","DOI":"10.18632\/oncotarget.16744","volume":"8","author":"M Perricone","year":"2017","unstructured":"Perricone M, Polverelli N, Martinelli G et al (2017) The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study. Oncotarget 8(23):37239\u201337249","journal-title":"Oncotarget"},{"issue":"1","key":"5754_CR100","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF03324948","volume":"23","author":"ML Randi","year":"2011","unstructured":"Randi ML, Ruzzon E, Tezza F et al (2011) JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia. Aging Clin Exp Res 23(1):17\u201321","journal-title":"Aging Clin Exp Res"},{"issue":"8","key":"5754_CR101","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1600-0463.2011.02754.x","volume":"119","author":"M Risum","year":"2011","unstructured":"Risum M, Madelung A, Bondo H et al (2011) The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis. APMIS 119(8):498\u2013504","journal-title":"APMIS"},{"issue":"7","key":"5754_CR102","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/ajh.24377","volume":"91","author":"G Rotunno","year":"2016","unstructured":"Rotunno G, Pacilli A, Artusi V et al (2016) Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group. Am J Hematol 91(7):681\u2013686","journal-title":"Am J Hematol"},{"issue":"2","key":"5754_CR103","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/ajh.25677","volume":"95","author":"E Sant\u2019Antonio","year":"2020","unstructured":"Sant\u2019Antonio E, Guglielmelli P, Pieri L et al (2020) Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases. Am J Hematol 95(2):156\u2013166","journal-title":"Am J Hematol"},{"issue":"2","key":"5754_CR104","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood.2019000519","volume":"134","author":"F Schischlik","year":"2019","unstructured":"Schischlik F, J\u00e4ger R, Rosebrock F et al (2019) Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. Blood 134(2):199\u2013210. https:\/\/doi.org\/10.1182\/blood.2019000519","journal-title":"Blood"},{"issue":"12","key":"5754_CR105","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.3324\/haematol.2020.264143","volume":"106","author":"M Schino","year":"2021","unstructured":"Schino M, Fiorentino V, Rossi E et al (2021) Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms. Haematologica 106(12):3162\u20133169","journal-title":"Haematologica"},{"issue":"2","key":"5754_CR106","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12185-014-1721-9","volume":"101","author":"S Shirane","year":"2015","unstructured":"Shirane S, Araki M, Morishita S et al (2015) Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia. Int J Hematol 101(2):148\u2013153","journal-title":"Int J Hematol"},{"issue":"10","key":"5754_CR107","first-page":"4647","volume":"17","author":"R Singdong","year":"2016","unstructured":"Singdong R, Siriboonpiputtana T, Chareonsirisuthigul T et al (2016) Characterization and prognosis significance of JAK2 (V617F), MPL, and CALR mutations in Philadelphia-Negative myeloproliferative neoplasms. Asian Pac J Cancer Prev 17(10):4647\u20134653","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"5754_CR108","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/modpathol.2017.182","volume":"31","author":"CR Soderquist","year":"2018","unstructured":"Soderquist CR, Ewalt MD, Czuchlewski DR et al (2018) Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Mod Pathol 31(5):690\u2013704. https:\/\/doi.org\/10.1038\/modpathol.2017.182","journal-title":"Mod Pathol"},{"issue":"4","key":"5754_CR109","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/ejh.13292","volume":"103","author":"AL S\u00f8rensen","year":"2019","unstructured":"S\u00f8rensen AL, Bj\u00f8rn ME, Riley CH et al (2019) B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: influence of ruxolitinib, interferon-\u03b12, or combination treatment. Eur J Haematol 103(4):351\u2013361","journal-title":"Eur J Haematol"},{"issue":"1","key":"5754_CR110","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/bjh.17130","volume":"193","author":"AL S\u00f8rensen","year":"2021","unstructured":"S\u00f8rensen AL, Knudsen TA, Skov V et al (2021) Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: a retrospective cohort study. Br J Haematol 193(1):83\u201392. https:\/\/doi.org\/10.1111\/bjh.17130","journal-title":"Br J Haematol"},{"key":"5754_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2022.01.011","volume":"211","author":"S Soudet","year":"2022","unstructured":"Soudet S, Le Roy G, Cadet E et al (2022) JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis. Thromb Res 211:1\u20135","journal-title":"Thromb Res"},{"issue":"9","key":"5754_CR112","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa1403141","volume":"371","author":"JL Spivak","year":"2014","unstructured":"Spivak JL, Considine M, Williams DM et al (2014) Two clinical phenotypes in polycythemia vera. N Engl J Med 371(9):808\u2013817","journal-title":"N Engl J Med"},{"key":"5754_CR113","doi-asserted-by":"publisher","first-page":"874146","DOI":"10.1155\/2011\/874146","volume":"2011","author":"BL Stein","year":"2011","unstructured":"Stein BL, Rademaker A, Spivak JL, Moliterno AR (2011) Gender and vascular complications in the JAK2 V617F-Positive myeloproliferative neoplasms. Thrombosis 2011:874146","journal-title":"Thrombosis"},{"issue":"2","key":"5754_CR114","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1365-2141.2005.05743.x","volume":"131","author":"A Tefferi","year":"2005","unstructured":"Tefferi A, Sirhan S, Lasho TL et al (2005) Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol 131(2):166\u2013171","journal-title":"Br J Haematol"},{"key":"5754_CR115","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bcmd.2018.09.003","volume":"73","author":"AP Trifa","year":"2018","unstructured":"Trifa AP, B\u0103nescu C, Voina CM et al (2018) Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycthemia vera and essential thrombocythemia. Blood Cells Mol Dis 73:45\u201346","journal-title":"Blood Cells Mol Dis"},{"issue":"10","key":"5754_CR116","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00277-010-0960-y","volume":"89","author":"AP Trifa","year":"2010","unstructured":"Trifa AP, Cucuianu A, Petrov L et al (2010) The G allele of the JAK2 rs10974944 SNP, part of JAK2 46\/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms. Ann Hematol 89(10):979\u2013983","journal-title":"Ann Hematol"},{"issue":"2","key":"5754_CR117","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3109\/10428194.2015.1049171","volume":"57","author":"C Utke Rank","year":"2016","unstructured":"Utke Rank C, Weis Bjerrum O, Larsen TS et al (2016) Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma 57(2):348\u2013354","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"5754_CR118","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000324436","volume":"126","author":"C Vadikolia","year":"2011","unstructured":"Vadikolia C, Tsatalas C, Anagnostopoulos K et al (2011) Proteolytic matrix metallopeptidases and inhibitors in BCR-ABL1-Negative myeloproliferative neoplasms: correlation with JAK2\u2009<\u2009sup\u2009>\u2009V617F mutation status. Acta Haematol 126(1):54\u201362","journal-title":"Acta Haematol"},{"issue":"4","key":"5754_CR119","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3343\/alm.2018.38.4.296","volume":"38","author":"N Yang","year":"2018","unstructured":"Yang N, Park S, Cho M et al (2018) GATA1 expression in BCR\/ABL1-negative myeloproliferative neoplasms. Ann Lab Med 38(4):296\u2013305","journal-title":"Ann Lab Med"},{"issue":"6","key":"5754_CR120","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/jcla.21981","volume":"30","author":"E Yoo","year":"2016","unstructured":"Yoo E, Park K, Won H et al (2016) Genetic characteristics of Polycythemia Vera and essential thrombocythemia in Korean patients. Clin Lab Anal 30(6):1061\u20131070","journal-title":"Clin Lab Anal"},{"issue":"3","key":"5754_CR121","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/MBC.0b013e32835bfdb9","volume":"24","author":"M Zangari","year":"2013","unstructured":"Zangari M, Fink L, Tolomelli G et al (2013) Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera? Blood Coagul Fibrinolysis 24(3):311\u2013316","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"6","key":"5754_CR122","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1002\/cam4.2886","volume":"9","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhou Y, Wang Y et al (2020) Thrombosis among 1537 patients with JAK2V617F-mutated myeloproliferative neoplasms: risk factors and development of a predictive model. Cancer Med 9(6):2096\u20132105","journal-title":"Cancer Med"},{"issue":"3","key":"5754_CR123","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3324\/haematol.2017.181297","volume":"103","author":"JC Ianotto","year":"2018","unstructured":"Ianotto JC, Chauveau A, Boyer-Perrard F et al (2018) Benefits and pitfalls of pegylated interferon-\u03b12a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica 103(3):438\u2013446. https:\/\/doi.org\/10.3324\/haematol.2017.181297","journal-title":"Haematologica"},{"issue":"5","key":"5754_CR124","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","volume":"36","author":"JJ Kiladjian","year":"2022","unstructured":"Kiladjian JJ, Klade C, Georgiev P et al (2022) Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia 36(5):1408\u20131411. https:\/\/doi.org\/10.1038\/s41375-022-01528-x","journal-title":"Leukemia"},{"key":"5754_CR125","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-141223","volume":"136:S1","author":"RD de Oliveira","year":"2020","unstructured":"de Oliveira RD, Soret Dulphy J, Zhao LP et al (2020) Interferon-Alpha (IFN) Therapy discontinuation is feasible in Myeloproliferative Neoplasm (MPN) patients with complete hematological remission. Blood 136:S1:35\u201336. https:\/\/doi.org\/10.1182\/blood-2020-141223","journal-title":"Blood"},{"issue":"19","key":"5754_CR126","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1200\/JCO.22.01935","volume":"41","author":"CN Harrison","year":"2023","unstructured":"Harrison CN, Nangalia J, Boucher R et al (2023) Ruxolitinib Versus Best available therapy for Polycythemia Vera intolerant or resistant to Hydroxycarbamide in a Randomized Trial. J Clin Oncol 41(19):3534\u20133544. https:\/\/doi.org\/10.1200\/JCO.22.01935","journal-title":"J Clin Oncol"},{"issue":"10","key":"5754_CR127","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/s41375-023-02008-6","volume":"37","author":"H Gisslinger","year":"2023","unstructured":"Gisslinger H, Klade C, Georgiev P et al (2023) Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. Leukemia 37(10):2129\u20132132. https:\/\/doi.org\/10.1038\/s41375-023-02008-6","journal-title":"Leukemia"},{"issue":"16","key":"5754_CR128","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1182\/blood.2022017697","volume":"141","author":"AR Moliterno","year":"2023","unstructured":"Moliterno AR, Kaizer H, Reeves BN (2023) JAK2 V617F allele burden in polycythemia vera: burden of proof. Blood 141(16):1934\u20131942. https:\/\/doi.org\/10.1182\/blood.2022017697","journal-title":"Blood"},{"issue":"3","key":"5754_CR129","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/cncr.30325","volume":"123","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Miller CB, Thyne M et al (2017) Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: findings from the MPN Landmark survey. Cancer 123(3):449\u2013458. https:\/\/doi.org\/10.1002\/cncr.30325","journal-title":"Cancer"},{"key":"5754_CR130","doi-asserted-by":"publisher","first-page":"204062072311793","DOI":"10.1177\/20406207231179331","volume":"14","author":"TH Tsai","year":"2023","unstructured":"Tsai TH, Yu LH, Yu MS et al (2023) Real-world patient characteristics and treatment patterns of polycythemia vera in Taiwan between 2016 and 2017: a nationwide cross-sectional study. Ther Adv Hematol 14:20406207231179331 Published 2023 Jun 15. https:\/\/doi.org\/10.1177\/20406207231179331","journal-title":"Ther Adv Hematol"},{"key":"5754_CR131","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1186\/s12885-018-4422-6","volume":"18","author":"S Parasuraman","year":"2018","unstructured":"Parasuraman S, Yu J, Paranagama D et al (2018) Cytoreductive treatment patterns among US veterans with polycythemia vera. BMC Cancer 18:528\u2013018","journal-title":"BMC Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05754-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05754-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05754-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T03:08:27Z","timestamp":1715569707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05754-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":131,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["5754"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05754-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]},"assertion":[{"value":"26 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Justin L. Chen was a contract researcher for Panco Healthcare Co., Ltd, a Pharmaessentia Company. Mr. Alex Jia-Hong Lin and Dr. Lennex Hsueh-Lin Yu are full-time employees for Panco Healthcare Co., Ltd, a Pharmaessentia Company. Dr. Hsin-An Hou and Dr. Chih-Cheng Chen declare honorarium, travel, and research support from PharmaEssentia Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}